Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Kegg Fertility Study is exploring a new way to help women track their fertility by using a device that measures changes in cervical mucus. This device, called the Kegg, is designed to provide real-time information about a woman's fertility status from the comfort of her home. Traditional methods, like calendar tracking or temperature measurements, may not accurately capture the full fertile window. The Kegg device aims to improve this by offering a more precise alternative, potentially making it easier for women who are trying to conceive.
To participate in this study, women need to be between 18 and 40 years old, able to read and understand English, and must have completed training on observing cervical mucus. They also need to own a compatible smart device and have internet access. Participants will learn how to use the Kegg device and will be involved in tracking their fertility status over time. This study is currently recruiting participants and could provide valuable insights into more effective fertility tracking methods.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Biological female
- • 2. Age between 18-40 years old
- • 3. Participant has provided signed informed consent
- • 4. Completed cervical mucus observation training
- • 5. Owns and uses daily a smart device meeting the following requirement: Apple iPad or iPhone running iOS 13 or newer, or Apple Watch running WatchOS 6.0 or newer, or Android operating system of 6.0 or newer
- • 6. Has readily accessible internet
- • 7. Legal residents of the continental United States, excluding Alaska and Hawaii.
- Exclusion Criteria:
- • 1. Participant is unable to read and understand English
- • 2. Postmenopausal women
- • 3. Women with hysterectomy
- • 4. Pregnancy
- • 5. Hormonal or intrauterine contraceptives or other hormone use prior to start of study enrollment \[No oral hormonal contraceptives or other hormones for at least one month, no implantable contraceptives or hormonal or non-hormonal intrauterine device for at least two months (\~2 cycles), no injectable hormonal contraceptives or other hormones in past 9 months from the most recent injection and resumption of regular menstrual cycles
About Lady Technologies Inc
Lady Technologies Inc. is a pioneering clinical trial sponsor dedicated to advancing women's health through innovative research and development. With a focus on addressing unmet medical needs, the company leverages cutting-edge technology and rigorous scientific methodologies to design and conduct clinical trials that prioritize patient safety and efficacy. Lady Technologies Inc. collaborates with a network of healthcare professionals and researchers to deliver impactful solutions, aiming to enhance the quality of life for women worldwide. Committed to transparency and ethical practices, the company strives to contribute to the future of healthcare by providing valuable insights and data-driven outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported